Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720746 | 1.00 | CYP1A2 (0.50) | CYP1A2MAPTTP53ALDH1A1PKM | |
| SCHEMBL643933 | 1.00 | CYP1A2 (0.50) | CYP1A2MAPTTP53ALDH1A1PKM | |
| SCHEMBL2655373 | 0.88 | LMNA (0.45) | CYP1A2MAPTTP53ALDH1A1PKM | |
| SCHEMBL2655368 | 0.88 | LMNA (0.45) | CYP1A2MAPTTP53ALDH1A1PKM | |
| SCHEMBL2655371 | 0.88 | LMNA (0.45) | CYP1A2MAPTTP53ALDH1A1PKM | |
| SCHEMBL642421 | 0.86 | MAPT (0.44) | CYP1A2MAPTTP53ALDH1A1PKM | |
| SCHEMBL642420 | 0.86 | MAPT (0.44) | CYP1A2MAPTTP53ALDH1A1PKM | |
| SCHEMBL642422 | 0.86 | MAPT (0.44) | CYP1A2MAPTTP53ALDH1A1PKM | |
| SCHEMBL12101425 | 0.85 | TSHR (0.54) | CYP1A2MAPTTP53ALDH1A1PKM | |
| SCHEMBL20163172 | 0.83 | MEN1 (0.56) | CYP1A2MAPTTP53ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8735396-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735396-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735396-B2 | Benzofuranyl derivatives | PFIZER INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130252973-A1 | Benzofuranyl Derivatives | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252973-A1 | Benzofuranyl Derivatives | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252973-A1 | Benzofuranyl Derivatives | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| EP-2406253-B1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2406253-B1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2604604-A1 | Benzofuranyl derivatives used as glucokinase inhibitors | Pfizer Inc (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20100234285-A1 | Benzofuranyl Derivatives | PFIZER INC | 2010-09-16 | — | — | US | disclosed |
| US-20100234285-A1 | Benzofuranyl Derivatives | PFIZER INC | 2010-09-16 | — | — | US | disclosed |
| WO-2010103437-A1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103437-A1 | BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234285-A1 | Benzofuranyl Derivatives | PFIZER INC | 2010-09-16 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234285-A1 | Benzofuranyl Derivatives | GCK, GCKR, GALK1 | CYP1A2 753/4885MAPT 2533/4885TP53 3801/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | CYP1A2 915/4885MAPT 3264/4885TP53 1900/4885 |
| US-20130252973-A1 | Benzofuranyl Derivatives | GCK, GCKR, GALK1 | CYP1A2 753/4885MAPT 2533/4885TP53 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.